PI3K Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which regulates cell growth, motility, survival, metabolism, and angiogenesis. Activation of the PI3K pathway contributes to the development of tumor PI3K/AKT/(mTOR). PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors, and isoform-specific inhibitors. They inhibit the (PI3K)/AKT signaling pathway, thereby resulting in decreased cellular proliferation and increased cellular death. PI3K inhibitors are indicated for HER2-negative breast cancer, chronic lymphocytic leukemia, follicular lymphoma, marginal zone B-cell lymphoma, angiomyolipoma, and astrocytoma. Novartis, AbbVie, Bayer, Gilead Sciences, Roche, Genentech, Abbott, GSK, and Eli Lilly & Company are some of the major players in the PI3K inhibitors market.

Key Market Developments:

• In Jan 2022, Gilead Sciences launched Idelalisib for chronic lymphocytic leukemia as first-line therapy in the UK, and as second-line therapy in New Zealand and Australia.
• In Jan 2023, Secura Bio’s Duvelisib received Orphan Drug status for peripheral T-cell lymphoma in the European Union.

Approved Drug Molecules and Brand Names for PI3K Inhibitors:

• Piqray (Alpelisib)
• Aliqopa (Copanlisib)
• Copiktra (Duvelisib)
• Zydelig (Idelalisib)
• Vijoice (Alpelisib)
• Fyarro (Sirolimus protein-bound particles for injectable suspension)
• Perjeta (Pertuzumab)
• Intarel (Linperlisib)
• Kisqali (Ribociclib)
• Ibrance (Palbociclib)
• Verzenio (Abemaciclib)
• Afinitor (Everolimus)

Drugs under the Pipeline for PI3K Inhibitors:

• Ganetespib (ADX-1612)
• GSK2636771
• Paxalisib
• MEN1611
• Gedatolisib
• TL117
• IBI376
• IPI-549 (Enganelisib)
• Ribociclib
• HMPL-689
• BYL719

Clinical Activity and Developments of PI3K Inhibitors:

Currently, there are more than 20 drug products in the PI3K inhibitors, including 12 approved drug products and the rest of them are in the clinical development phases.

• In June 2023, Medica Scientia Innovation Research and Roche released updated efficacy data from a phase-II clinical trials in breast cancer for Pertuzumab.
• In March 2023, Novartis completed a phase-III clinical trials in breast cancer for Ribociclib in the USA, Argentina, Australia, Belgium, Brazil, France, Canada, Russia, Spain, Switzerland, and others.